Nexus Pharmaceuticals v. Hikma: Ephedrine Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA, Inc. |
| Case Number | 1:25-cv-00018 |
| Court | U.S. District Court for the District of Delaware |
| Duration | Jan 2025 – Jan 2026 1 year 1 month (387 days) |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Hikma’s ephedrine sulfate 25 mg/5 mL (5 mg/mL) product |
Case Overview
The Parties
⚖️ Plaintiff
Specialty pharmaceutical company focused on injectable and infusion drug products, asserting its formulation IP portfolio to protect market position.
🛡️ Defendant
U.S. subsidiary of a major global generic and specialty pharmaceutical manufacturer, frequently involved in Hatch-Waxman and related patent disputes.
Patents at Issue
This dispute involved three U.S. patents asserted by Nexus, covering formulation technologies associated with ephedrine sulfate. These patents protect the ornamental appearance rather than functional technology.
- • US 11,426,369 B2 — Formulation technology for ephedrine sulfate
- • US 11,571,398 B1 — Dosage form innovations for ephedrine sulfate
- • US 11,464,752 B2 — Stability-enhancing features for ephedrine sulfate
Developing a similar pharmaceutical formulation?
Check if your ephedrine sulfate product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was dismissed without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii) by joint stipulation of the parties. This means:
- No damages, attorneys’ fees, or costs were awarded to either party.
- No injunctive relief was granted or denied by the court.
- Nexus retains the right to re-file infringement claims on the same patents against Hikma, subject to any private agreements.
- The District Court for the District of Delaware retained jurisdiction, suggesting a private resolution with ongoing obligations between the parties.
Legal Significance
Because the dismissal was reached by agreement, no judicial rulings on claim construction, infringement, or patent validity were issued. The asserted claims of the ‘369, ‘398, and ‘752 patents therefore remain fully enforceable assets for Nexus. The “without prejudice” designation, combined with the retained court jurisdiction, is a strong indicator that the parties likely reached a confidential settlement or licensing agreement to resolve the dispute, allowing Hikma market access while respecting Nexus’s intellectual property. This outcome is strategically significant for both parties and the broader pharmaceutical IP landscape.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in specialty pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in ephedrine sulfate technology space
- See which companies are most active in injectable formulation IP
- Understand patenting and litigation trends in vasopressors
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical formulation or product.
- Input your drug description or technical features
- AI identifies potentially blocking formulation patents
- Get actionable infringement risk assessment report
High Risk Area
Ephedrine sulfate formulations & dosages
3 Patents Asserted
In this litigation alone
Strategic Design-Arounds
Possible with early FTO
✅ Key Takeaways
Stipulated dismissals with retained jurisdiction often signal private settlements with ongoing obligations, warranting monitoring for future enforcement.
Search related case law →The absence of judicial rulings preserves claim construction flexibility and patent validity for future assertions.
Explore precedents →Injectable drug formulations, especially for critical care agents like ephedrine sulfate, are active patent enforcement areas.
Monitor pharmaceutical patent trends →Comprehensive FTO analysis should be a priority before finalizing any new pharmaceutical formulation or dosage form.
Request FTO consultation →Frequently Asked Questions
Three U.S. patents: Nos. 11,426,369 B2; 11,571,398 B1; and 11,464,752 B2, all related to ephedrine sulfate formulation technology.
The parties stipulated to dismissal under FRCP 41(a)(1)(A)(ii) by mutual agreement, with no costs awarded. The court retained jurisdiction, suggesting a private resolution with ongoing obligations.
The Nexus patents remain valid and enforceable, creating continued risk for generic manufacturers entering this product space without a license or design-around strategy.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER (Public Access to Court Electronic Records) — Case No. 1:25-cv-00018
- USPTO Patent Full-Text and Image Database
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)(1)(A)(ii)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.